JAZZ
Income statement / Annual
Last year (2025), Jazz Pharmaceuticals plc's total revenue was $4.27 B,
an increase of 4.88% from the previous year.
In 2025, Jazz Pharmaceuticals plc's net income was -$356.15 M.
See Jazz Pharmaceuticals plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$4.27 B |
$4.07 B |
$3.83 B |
$3.66 B |
$3.09 B |
$2.36 B |
$2.16 B |
$1.89 B |
$1.62 B |
$1.49 B |
| Cost of Revenue |
$503.30 M
|
$445.71 M
|
$435.58 M
|
$540.52 M
|
$440.76 M
|
$148.92 M
|
$127.93 M
|
$121.54 M
|
$110.19 M
|
$105.39 M
|
| Gross Profit |
$3.76 B
|
$3.62 B
|
$3.40 B
|
$3.12 B
|
$2.65 B
|
$2.21 B
|
$2.03 B
|
$1.77 B
|
$1.51 B
|
$1.38 B
|
| Gross Profit Ratio |
0.88
|
0.89
|
0.89
|
0.85
|
0.86
|
0.94
|
0.94
|
0.94
|
0.93
|
0.93
|
| Research and Development Expenses |
$782.74 M
|
$884.00 M
|
$849.66 M
|
$590.45 M
|
$505.75 M
|
$335.38 M
|
$299.73 M
|
$226.62 M
|
$198.44 M
|
$162.30 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.81 B
|
$1.39 B
|
$1.34 B
|
$1.42 B
|
$1.45 B
|
$854.23 M
|
$736.94 M
|
$683.53 M
|
$544.16 M
|
$502.89 M
|
| Other Expenses |
$947.86 M
|
$637.31 M
|
$627.28 M
|
$1.18 B
|
$525.77 M
|
$646.97 M
|
$464.79 M
|
$244.39 M
|
$237.07 M
|
$125.74 M
|
| Operating Expenses |
$3.54 B
|
$2.91 B
|
$2.82 B
|
$3.18 B
|
$2.48 B
|
$1.84 B
|
$1.50 B
|
$1.15 B
|
$979.66 M
|
$790.93 M
|
| Cost And Expenses |
$4.04 B
|
$3.35 B
|
$3.26 B
|
$3.72 B
|
$2.92 B
|
$1.99 B
|
$1.63 B
|
$1.28 B
|
$1.09 B
|
$896.32 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$195.05 M
|
$238.10 M
|
$289.44 M
|
$288.24 M
|
$278.77 M
|
$99.71 M
|
$72.26 M
|
$78.50 M
|
$77.76 M
|
$61.94 M
|
| Depreciation & Amortization |
$542.00 M
|
$660.07 M
|
$638.70 M
|
$629.47 M
|
$552.48 M
|
$278.25 M
|
$370.16 M
|
$216.73 M
|
$165.15 M
|
$113.78 M
|
| EBITDA |
$108.46 M |
$1.52 B |
$1.45 B |
$1.47 B |
$1.03 B |
$1.04 B |
$1.01 B |
$932.67 M |
$779.00 M |
$753.88 M |
| EBITDA Ratio |
0.03
|
0.37
|
0.38
|
0.4
|
0.33
|
0.44
|
0.47
|
0.49
|
0.48
|
0.51
|
| Operating Income Ratio |
0.05
|
0.18
|
0.15
|
-0.02
|
0.06
|
0.16
|
0.25
|
0.33
|
0.33
|
0.4
|
| Total Other Income/Expenses Net |
-$853.01 M
|
-$247.94 M
|
-$283.66 M
|
-$317.18 M
|
-$283.83 M
|
-$105.94 M
|
-$82.16 M
|
-$87.58 M
|
-$88.73 M
|
-$59.59 M
|
| Income Before Tax |
-$628.59 M
|
$468.69 M
|
$294.92 M
|
-$382.71 M
|
-$113.55 M
|
$272.13 M
|
$450.21 M
|
$527.26 M
|
$440.11 M
|
$532.07 M
|
| Income Before Tax Ratio |
-0.15
|
0.12
|
0.08
|
-0.1
|
-0.04
|
0.12
|
0.21
|
0.28
|
0.27
|
0.36
|
| Income Tax Expense |
-$272.44 M
|
-$91.43 M
|
-$119.91 M
|
-$158.65 M
|
$216.12 M
|
$33.52 M
|
-$73.15 M
|
$80.16 M
|
-$47.74 M
|
$135.24 M
|
| Net Income |
-$356.15 M
|
$560.12 M
|
$414.83 M
|
-$224.06 M
|
-$328.95 M
|
$238.62 M
|
$523.37 M
|
$447.10 M
|
$487.85 M
|
$396.83 M
|
| Net Income Ratio |
-0.08
|
0.14
|
0.11
|
-0.06
|
-0.11
|
0.1
|
0.24
|
0.24
|
0.3
|
0.27
|
| EPS |
-5.84 |
9.06 |
6.55 |
-3.58 |
-5.51 |
4.28 |
9.22 |
7.45 |
8.13 |
6.56 |
| EPS Diluted |
-5.84 |
8.65 |
6.1 |
-3.58 |
-5.51 |
4.22 |
9.09 |
7.3 |
7.96 |
6.41 |
| Weighted Average Shares Out |
$60.98 M
|
$61.84 M
|
$63.29 M
|
$62.54 M
|
$59.69 M
|
$55.71 M
|
$56.75 M
|
$59.98 M
|
$60.02 M
|
$60.50 M
|
| Weighted Average Shares Out Diluted |
$60.98 M
|
$66.01 M
|
$72.07 M
|
$62.54 M
|
$59.69 M
|
$56.52 M
|
$57.55 M
|
$61.22 M
|
$61.32 M
|
$61.87 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
